Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267577 · ClinicalTrials.gov registry record · NA
Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Adult Volunteers
A NA study, sponsored by William Marsh Rice University.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT02267577: Completed NA study, sponsored by William Marsh Rice University.
NCT02267577 is a NA study that has completed, run by William Marsh Rice University. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02267577, a NA study, has completed, sponsored by William Marsh Rice University.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The research team has developed an automatic blood pressure monitor (Sphygmo) to be used for the monitoring and diagnosis of pre-eclampsia in pregnant women, particularly in low-resource settings where current monitoring is limited. 90 adult volunteers will be enrolled by researchers at Rice University. The participant will be seated in a comfortable chair with arm at heart level. Arm circumference will be measured and a blood pressure cuff will be placed on the arm. The cuff will be inflated and blood pressure measurements will be taken by a commercially available device and by the Sphygmo device. Blood pressure measurements from both devices will be recorded. The participant's blood pressure will be measured up to 9 times with a waiting period of 45-60 seconds between each measurement. The results of this study will be used to optimize the blood pressure detection algorithm and thus further develop the device.
Primary Outcome
Mean difference of systolic and diastolic blood pressure readings between Sphygmo device and the gold standard sphygmomanometer.
Interventions
- DEVICE Sphygmo: Automatic Blood Pressure Monitor
- DEVICE GE Dinamap ProCare Automatic Blood Pressure Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-10-12 |
| Phase | NA |
What the finished NCT02267577 record still lists
NCT02267577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Sphygmo: Automatic Blood Pressure Monitor is the first listed.
NCT02267577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02267577 about?
NCT02267577 is a clinical study titled "Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Adult Volunteers". The research team has developed an automatic blood pressure monitor (Sphygmo) to be used for the monitoring and diagnosis of pre-eclampsia in pregnant women, particularly in low-resource settings where current monitoring is limited. 90 adult volunteers will be enrolled by researchers at Rice Univer...
What is the current status of trial NCT02267577?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2015-01. Estimated completion is 2017-10-12.
What interventions are being tested in trial NCT02267577?
The interventions under investigation include: Sphygmo: Automatic Blood Pressure Monitor (DEVICE), GE Dinamap ProCare Automatic Blood Pressure Monitor (DEVICE).
Who is sponsoring clinical trial NCT02267577?
This trial is sponsored by William Marsh Rice University, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02267577's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia